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ABSTRACT Microneedlepatches(MN)provideanovelmethodofvaccinedeliverytotheskinwiththeobjectiveoftargetingthe
largenetworkofresidentantigen-presentingcellstoinduceanefﬁcientimmuneresponse.Ourpreviousreportsdemonstrated
thatcutaneousdeliveryofinactivatedinﬂuenzavirus-coatedMNtomiceprotectsagainstlethalinfection.Protectioniscorre-
latedwithsustainedlevelsofanti-inﬂuenzavirusserumantibodies,hemagglutinationinhibitiontiters,androbustcellularre-
sponsesthatareoftenstrongerthanthosegeneratedbyintramuscularvaccination.Herewedissecttheearlyeventsoccurringin
murineskinaftermicroneedledeliveryofinactivatedinﬂuenzavirus.Wedemonstratecorrelationofimmunizationagainstin-
ﬂuenzaviruswithalocalincreaseofcytokinesimportantforrecruitmentofneutrophils,monocytesanddendriticcellsatthe
siteofimmunization.Wealsoobservedprolongedantigendeposition,andmigrationofmatureddendriticcellsbearinginﬂu-
enzavirusantigenfromtheskin.
IMPORTANCE TheimmunologicalmechanismsbywhichMNvaccinationconfersprotectiveimmunityarenotwellunderstood.
Thepresentstudyprovidesaﬁrstanalysisoftheearlyimmuneeventsaftermicroneedle-basedvaccination.
Received 12 January 2012 Accepted 2 February 2012 Published 6 March 2012
Citation del Pilar Martin M, et al. 2012. Local response to microneedle-based inﬂuenza immunization in the skin. mBio 3(2):e00012-12. doi:10.1128/mBio.00012-12.
Editor Jack Bennink, National Institute of Allergy and Infectious Diseases
Copyright © 2012 del Pilar Martin et al. This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0
Unported License, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original author and source are credited.
Address correspondence to Richard W. Compans, rcompan@emory.edu.
V
accination against infectious agents remains the most effec-
tivemethodofdiseasepreventionandoneofthemostimpor-
tant health advances in history. Vaccines prevent or ameliorate
infection based on two fundamental principles: the generation of
a rapid and effective immune response, and long-lived speciﬁc
immunity. Despite the success of vaccination, a number of chal-
lenging pathogens continue to elude complete protection by vac-
cines due to their rapid mutation capacity and/or the variety of
subtypes that exist in nature. Due to the antigenic diversity ob-
served among inﬂuenza virus strains and limited duration of the
immune response to inactivated vaccines, annual vaccination is
required (1). The inﬂuenza vaccine composition is determined
every year based on the analysis of inﬂuenza surveillance activity
reports,whichhelptoestimatewhichstrainsofvirusareexpected
to circulate in the human population (2). Efﬁcacy of the inacti-
vated inﬂuenza vaccine is correlated with seroconversion against
themajorinﬂuenzasurfaceprotein,thehemagglutinin(3,4).Ac-
ceptable levels of hemagglutinin antibody titers are normally
achievedbyhigherdosesand/ormultipledosesinindividualswho
havenotbeenpreviouslyexposedtoaninﬂuenzavirusofthesame
subtype(5).Inﬂuenzavaccinationcouldbeneﬁtfromnewvaccine
formulations and novel vaccine delivery methods that provide an
enhanced immune response.
Alternate routes of vaccination to the conventional intramus-
cular delivery have been found to produce enhanced immune re-
sponses, and in humans, a nasally administered live attenuated
inﬂuenzavaccinehasalsoproventobeeffective(6).However,this
vaccine is approved only for healthy individuals 2 through
49yearsofage,whichexcludesthoseathighestriskfordeveloping
inﬂuenza-related complications, such as infants, elderly persons,
and immunocompromised individuals (7). One very attractive
and promising alternative route of immunization is the skin. In
2011, the U.S. Food and Drug Administration (FDA) approved
theﬁrstdermallyadministeredinﬂuenzavaccineforhumanusein
theUnitedStates(8,9).Theskinisnotmerelyaphysicalbarrier;a
large body of work has demonstrated that the skin is also a com-
plexandactiveimmunesite.Intradermaldeliveryprovidesaccess
to the dense network of antigen-presenting cells, including mac-
rophages, Langerhans cells, and dermal dendritic cells (DC) pres-
entinthedermisandepidermis,whicharecrucialintheinitiation
of the adaptive immune response and provide a favorable site for
immunization (10, 11).
Recent work from our laboratories and others has shown that
vaccine delivery via the skin using metal microneedle patches
(MN) coated with inﬂuenza antigens or dissolving microneedles
with encapsulated inactivated inﬂuenza virus results in enhanced
or equivalent protection compared to delivery via the conven-
tional intramuscular or subcutaneous routes (12–16). Challenge
studies in MN-immunized mice demonstrated complete protec-
tion against homosubtypic viruses. MN vaccination induced a
broadspectrumofimmuneresponses,includinghigherfrequency
ofvirus-speciﬁcCD4andCD8Tcells,virus-speciﬁcantibody-
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proﬁle compared to conventional intramuscular delivery. These
adaptive immune responses are the result of orchestrated events
initiatedbytheinnateimmunesystem,whichplaysafundamental
role in sensing microbes and danger signals through pattern rec-
ognition receptors (PRR) (17). The plasticity of DC subsets and
the PPR responses have been described as key initiating factors
that ultimately determine the quality of the adaptive immune re-
sponse (18). Therefore, we investigated the early events after MN
vaccination in order to gain new insights into the innate immu-
nological mechanisms involved in MN delivery.
In this study we dissected the events that occur in the skin at
earlytimepointsfollowinginﬂuenzaMNvaccinationinmice.We
analyzed the time course of antigen retention within the skin and
the release of inﬂammatory cytokines mediated by MN insertion.
Furthermore,weanalyzedtheegressofinﬂuenzaantigen-bearing
CD11c DC from the skin and their phenotype. These results
provide evidence of robust local innate immune responses gener-
atedbyMNdeliverytotheskin,andmayprovideinsightintohow
immune responses may differ depending on the vaccination
route.
RESULTS
Cytokineandchemokineexpressionintheskin.Afterantigenis
depositedwithintheskin,cytokinesandtheirsubsequentrecruit-
mentofimmunecellsatthesiteofdeliverymayplayanimportant
role in the robust adaptive immune response observed after MN
vaccination. To evaluate the innate responses that occur locally
afterMNdelivery,biopsiesoftissuefromtheMNinsertionsiteof
miceimmunizedwithinactivatedinﬂuenzavirusormockimmu-
nizedwithuncoatedmicroneedleswerecarriedoutandcompared
to naïve-skin biopsies. The biopsy samples were collected6ha n d
12 h postimmunization, and the levels of 31 murine cytokines
were compared between the groups.
After MN vaccination, we observed signiﬁcant increases in the
levels of the cytokines interleukin 1 (IL-1), macrophage in-
ﬂammatory protein 1 alpha (MIP-1), macrophage inﬂamma-
toryprotein2(MIP-2),tumornecrosisfactoralpha(TNF-),and
monocyte chemoattractant protein 1 (MCP-1) (Fig. 1A). These
cytokineswerealsoinduceduponinsertionofMNalone,buttheir
levels were further increased by immunization using MN coated
with inﬂuenza vaccine. These levels were further enhanced at the
12-h time point. The increase of these cytokine expression levels
has been demonstrated to contribute to the regulation of epider-
mal Langerhans cell migration and the subsequent accumulation
ofdendriticcellsinthedraininglymphnodes,inadditiontotheir
role in neutrophil and monocyte recruitment (19, 20).
The levels of other cytokines important for proliferation, acti-
vation, and recruitment of neutrophils and monocytes, such as
granulocyte colony-stimulating factor (G-CSF), interferon
gamma-induced protein 10 (IP-10), and cytokine-induced neu-
trophil chemoattractant (CXCL-1; also called CINC-1 or KC),
were also increased by MN vaccination (Fig. 1B). Although the
level of the important T helper 1 (Th1) chemokine IP-10 was
increased statistically after MN delivery, IL-12 and gamma inter-
feron, which characterize a Th1 response, were not found to be
expressed at elevated levels in the skin. In addition, leukemia in-
hibitory factor (LIF), a cytokine induced by TNF- and demon-
stratedtohaveananti-inﬂammatoryroleincutaneousinﬂamma-
tion (21), was modestly increased in the skin biopsy specimens
after vaccination. Therefore, these ﬁndings indicate that a rapid
increase of cytokines at the insertion site was induced by MN
mechanical skin penetration, which was enhanced upon antigen
delivery.Theskincytokineproﬁleanalysisshowsthatskinimmu-
nization induces a local innate immune response and a release of
chemokines in the skin suggestive of the activation and recruit-
ment of immune cells to the site of vaccination.
In vivo uptake and egress of labeled-inﬂuenza virus antigen
after MN immunization. To determine whether skin-resident
dendritic cells were mobilized after MN vaccination, we assessed
egressofcellsfromtheearsofmiceimmunizedwithlabeled(PR8-
Qdot) or antigen-free MN by an ex vivo skin organ assay. In this
assay, migrating cells exit the excised skin and collect in the me-
dium, where their phenotype can be determined by ﬂow cytom-
etry. Following MN vaccination, we detected inﬂuenza antigen-
positivecellemigrantsinthemediumfromtheearexplantswithin
theﬁrst2h(Fig.2).At2h,50%ofdendriticcells,characterizedby
the expression of the cell surface marker CD11c, were inﬂuenza
antigen positive (2.6  103  0.6  103 CD11c cells/explant).
The30-mintimepointshowedthehighestpercentageofantigen-
labeled cells; these represented 70% of the dendritic cells that had
egressed(6.61031.3103).ApopulationofCD11c-negative
cells was also found to peak at 30 min and to contain labeled
inﬂuenzavirusantigen(0.91030.1103).Cellslabeledwith
ﬂuorescent inﬂuenza virus were not detected at later time points.
These ﬁndings suggest that skin-resident dendritic cells capture
antigen and rapidly migrate to the draining lymph nodes, where
they present the antigen to naive lymphocytes. However, we did
not identify the ﬂuorescent inﬂuenza virus-loaded cells in the
draining lymph nodes when we examined them in the ﬁrst 3 days
postimmunization.
In order to characterize the phenotype of the skin explant em-
igrantsandtoassesstheirmaturationstatus,weusedﬂuorescently
labeled antibodies against CD40, major histocompatibility com-
plex class II (MHC II), and CD86 for ﬂow cytometry analysis.
These markers have been associated with dendritic cell matura-
tion and have been shown to be required for antigen presentation
(22, 23). CD11c cells that emigrated from the vaccinated skin
showed high expression levels of the cell surface markers MHC II
and CD205 and a low expression level of CD8 (Fig. 3A). In addi-
tion,morethan50%ofthesecellshadincreasedexpressionofthe
costimulatory markers CD40 and CD86, characteristic of acti-
vateddendriticcells.Furthermore,35%ofthesecellswerepositive
for Qdot-labeled inﬂuenza virus (Fig. 3B). We were not able to
detect any CD11c CD8– CD205 cells that were positive for
Qdot-labeled inﬂuenza virus (Fig. 3C). Expression of both CD40
and CD86 together with increased MHC class II expression sug-
gests that these skin-derived dendritic cells are activated and ma-
ture (24). This phenotype is required for T cell priming, and such
cells are likely to contribute to the strong immune response ob-
served with MN vaccination.
Invivowhole-bodyﬂuorescenceimagingofMN-immunized
mice.Tononinvasivelymonitorthedeliveryofantigentoskinvia
MN delivery, mice were immunized with ovalbumin-Alexa Fluor
488 (OVA 488)-coated needles, and the kinetics of the protein
retention in the skin were evaluated. The insertion site was mon-
itoredfor1week,imageswerecapturedat10minanddays1,2,3,
5,and8afterimmunization,andthelevelsofproteinﬂuorescence
were compared over time. We observed an intense deposition of
antigen corresponding to the site of microneedle array insertion
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immunizedgroupwhenexposuresettingswerekeptconstant(see
Fig. S1A in the supplemental material). The injection site of MN-
or intramuscularly (IM)-delivered ﬂuorescent OVA was detected
using a PANSEE imaging system in the caudal dorsal region and
ventral images of the quadriceps muscles, respectively. An IM-
immunized group was used as a comparator for antigen dissipa-
tion after immunization. No signs of erythema, edema, or indu-
ration were observed at the sites of injection in any of the groups.
Theﬂuorescenceintensitydissipatedwithtime,butevenatday8,
FIG1 InﬂammatorycytokinereleaseafterMNimmunizationwithinactivatedinﬂuenzavirus.Skinsampleswerecollected6hand12hafterMNimmunization
with 3 g of inactivated virus, and tissue lysates were evaluated for cytokine release by Luminex multiplex assay. The graphs show the concentrations of the
cytokines that were differentially expressed for the following mouse groups: C, naive control;6hN ,6 - hnaive shaved; 6 h MN, 6-h MN mock; 6 h MN/PR8, 6-h
PR8-coatedMN;12hN,12-hnaiveshaved;12hMN,12-hMNmock;and12hMN/PR8,12-hPR8-coatedMN.Dataarerepresentativeoftwoexperiments,and
data are means  SD (n  3). Asterisks indicate the statistical signiﬁcance of selected comparisons: *, P  0.05; **, P  0.01; and ***, P  0.001.
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gain and 20% higher illumination (data not shown). Analysis of
the integrated density revealed that 2 days following microneedle
insertion,approximatelyhalfoftheantigenremainedattheinjec-
tion site. The integrated intensity variation was more prominent
between IM samples, possibly as a result of the antigen delivery as
a suspension compared to the more localized antigen deposition
by MN delivery. In addition, a slightly higher dissipation of the
signal 3 days postvaccination was observed in the IM group. At
day 3, similar levels of antigen were still observed in the skin.
Approximately 2.5-fold more antigen was detected at the site of
MN vaccination than at the site of IM vaccination (Table 1).
To conﬁrm that the in vivo ﬂuorescence signals of OVA accu-
ratelyrepresentedthelocalizationofinactivatedinﬂuenzavaccine
and to improve the imaging detection level, inactivated virus was
labeledwithQdot705nanocrystals(Qdot)andvisualizedwiththe
CRi Maestro EX in vivo imaging system, which allows the detec-
tionofbroaderemissionspectra.Tomoreaccuratelyrepresentthe
actualvaccinedose,5gofinactivatedlabeledinﬂuenzaviruswas
used to vaccinate the mice and commercially labeled streptavidin
FIG2 Transport of Qdot-labeled PR8 is primarily mediated by dermal dendritic cells. Qdot 655-labeled PR8 virus was used to coat MN and delivered into the
skin in the ears of BALB/c mice. Auricular emigrants of explants were harvested from mice 10 min, 30 min, 2 h, 24 h, and 48 h postimmunization. Shown are
representative ﬂow cytometry analyses of Qdot-positive populations of total live cell emigrants, CD11c-negative cells, and dendritic cells (CD11c).
FIG3 Dendritic cells draining from skin and bearing PR8-Qdot antigen exhibit a mature phenotype. Results of ﬂow cytometry analysis of DC emigrants from
auricular explants after MN vaccination are shown. (A) Cells were evaluated for the expression of MHCI class II (MHC II). (B) Highly MHC II-positive DC
(MHC II) showing a distinct population of CD8 CD205 DC. (C) Plots of the latter showing the expression of maturation markers CD40 and CD86 and
the prominent population positive for the PR8-Qdot label. The SD from two experiments with 3 to 5 mice are shown. (D) Fraction of MHC II DC negative
for CD8 expression.
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immunized mice were captured immediately after vaccination
and at days 1, 2, 3, 7, 14, and 21 after vaccination (Fig. 4A and B).
A concentrated deposition of antigen was observed at the site of
insertion that decreased approximately 4-fold by day 3 but was
still detectable at day 14 when skin was exposed for a longer pe-
riod.Inordertovisualizetheinsertionsite,theexposuretimewas
doubled for each of the mouse groups evaluated (22,000 ms
for d7a-d21a (Fig. 4A) and d3b-d21b (Fig. 4B) mice). The
streptavidin-Alexa750-treatedmicealsoshowedasimilarpattern
ofantigendepositionwithaslightlyhigherrateofdecrease(Table
2) than the labeled inactivated virus, as indicated by the residual
ﬂuorescenceatthesiteofinjection.Theslowreleaseofinactivated
inﬂuenza virus antigen from the skin correlates with the results
observed with OVA as a model antigen and supports the conclu-
sion that MN delivery results in prolonged deposition of antigen
in the skin.
DISCUSSION
Inﬂuenza vaccines with enhanced immunogenicity are needed to
improve protection, particularly for individuals at high risk of
inﬂuenza-relatedcomplications.Oneoftheapproachestoachieve
thisgoalistheevaluationofnewvaccinedeliveryroutes.Although
theefﬁcacyofintradermalvaccinationhasbeenproventobesuc-
cessful for vaccines such as those against bacillus Calmette-
Guérin, smallpox, rabies and, most recently, inﬂuenza, it is not
widely practiced for other vaccines (25). In recent studies, alter-
nativedeliveryapproachesdesignedtoreachthedermallayerhave
demonstrated successful vaccine delivery and protective immune
responsesinanimalmodels.Inclinicalstudies,intradermaldeliv-
ery of vaccine antigens, including inﬂuenza virus antigens, has
shown promising results (26). The main obstacle to the use of the
intradermal delivery route is the lack of an appropriate delivery
system that could circumvent the technically difﬁcult Mantoux
technique.Someexamplesoftechniquesthatpenetrateordisrupt
the outermost layer of the skin, the stratum corneum, rely on the
useofhypodermicmicroneedles,sandpaper,orelectricalcurrent.
PreviouslywedemonstratedthatMNimmunizationproduces
robustserumantibodyresponsesandcellularresponsescapableof
conferring protection against viral challenge at least as effectively
asmostconventionalimmunizationroutes(27).Importantly,an-
tibodytitersremainedelevatedintheMN-immunizedgroupeven
6 months after vaccination and correlated with inhibition of viral
replicationandrobustrecallTh1cellularresponsesafterinﬂuenza
virus challenge (28). Therefore, the immune responses observed
after a single MN dose not only are potent but also provide long-
term immunity.
In the present study, we evaluated the innate immune re-
sponses in the skin that precede the development of the inﬂuenza
virus-speciﬁc responses in order to investigate the mechanism of
vaccine-induced immunity. Keratinocytes make up approxi-
mately 90% of the total cell population of the skin and play an
important role in the innate immune response by secreting cyto-
kines,chemokines,andantimicrobialpeptidesinresponsetofor-
eign antigen (11, 29, 30). Cross-talk between keratinocytes and
Langerhans cells via these innate immune signals induces activa-
tion, maturation, and migration of antigen-presenting cells to
draining lymph nodes. The importance of IL-1 and TNF- in
induction of Langerhans cell migration from the epidermis has
been demonstrated in skin contact sensitization models and in
experimentalcutaneousLeishmaniainfections(31,32).Ouranal-
ysis of cytokine expression in the skin following insertion of
antigen-coated microneedles indicates the upregulation of IL-1,
TNF-, and MIP-1 and supports the current models of Langer-
hans cell migration. The induction of the chemotactic proteins
MIP-1, MIP-2, MCP-1, IP-10, G-CSF, and KC suggests that fol-
lowing antigen-coated microneedle vaccination, the production
of IL-1 and TNF- in the skin is reinforced by recruitment of
neutrophils and macrophages to the site of vaccination (33). Fur-
ther work is needed to determine if the cytokine pattern observed
isantigenspeciﬁc,andsuchstudiesmightofferapredictivesigna-
ture that could serve to rapidly evaluate novel vaccine formula-
tions.
Previous studies have demonstrated the migration of antigen-
loadedLangerhanscellsfrommouseskinandsubsequenthoming
to draining lymph nodes (34). Such migration is important in
priming naive lymphocytes and activation of the adaptive im-
mune response. Here we have demonstrated the migration of ac-
tivatedandmaturedantigen-loadedCD11cDCfromvaccinated
skin with antigen-coated microneedles. These antigen-loaded
CD11c DC also expressed low levels of CD8 and high levels of
CD205, indicating that they were of skin origin (35, 36). In addi-
tion,thesecellsexpressedhighlevelsofMHCIIandcostimulatory
molecules (CD86 and CD40), suggesting that they are capable of
efﬁcientactivationofnaiveantigen-speciﬁcTlymphocytes.These
results are consistent with previous studies indicating increased
expressionofCD80andCD86inLangerhanscellsmigratingfrom
murine skin explants (36, 37).
MacroimagingofmicevaccinatedwithQdot-labeledinﬂuenza
virusindicatesthatantigenisdepositedintheskinforupto7days
(Fig.4).Thisprolongeddepositionofantigensuggeststheforma-
tion of “antigen depots” at the sites of microneedle insertion. An-
tigendepotformationleadstoprolongedantigenrelease,allowing
efﬁcient uptake by antigen-presenting cells (38). Adjuvants such
as aluminum hydroxide and incomplete Freund’s adjuvant are
capable of forming antigen depots in addition to inducing the
production of proinﬂammatory cytokines and granulocyte-
recruiting chemokines, further serving their roles as immunos-
timulants (39, 40). It will be of interest to determine if the rate of
release of vaccine from an antigen depot might depend on the
large size of the inactivated virus antigen and the kinetics of anti-
gen trafﬁcking to the draining lymph nodes. In addition, we have
TABLE 1 Tissue-integrated ﬂuorescence density of labeled antigen
Group Density (mean  SD)a %
MN
d1 5.8  106  3.0  106 100
d2 2.9  106  0.5  106 50
d3 3.2  106  0.6  106 55
d5 0.6  106  0.1  106 10
d8 ND
IM
d1 4.3  106  2.8  106 100
d2 2.4  106  1.2  106 54
d3 1.3  106  0.4  106 28
d5 0.3  106  0.3  106 7
d8 ND
a The signal intensity was quantiﬁed using ImageJ software at the injection site from
images captured day 0 through day 8 after MN delivery or IM injection. ND, signal was
below detection level.
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site of microneedle vaccination, resulting in the production of
proinﬂammatory cytokines and chemokines. This early innate
signaling induces activation and maturation of skin antigen-
presenting cells, which have also captured antigen deposited by
microneedle insertion. These cells migrate to draining lymph
nodes, where they express CD40 and CD86 costimulatory mole-
cules. Taken together, these results indicate that the efﬁciency of
microneedle patch vaccination is controlled by the skin innate
immune response and the migration of skin dendritic cell popu-
lations to the draining lymph nodes.
Using surface cell markers selected for murine DC character-
ization, CD205 and CD11c, we identiﬁed inﬂuenza virus-loaded
DC and observed their migration from the skin, which suggests
the capacity to travel to the lymph nodes. Our goal was to deter-
mine whether inactivated inﬂuenza virus used as a vaccine and
delivered via MN was associated with skin dendritic cell matura-
tionandtocreateparallelstoresearchﬁndingsthathavetradition-
ally used ﬂuorophores and ovalbumin as model antigens. This is
of particular relevance in light of the differential T helper polar-
ization observed at various skin immunization sites, correlating
with site-speciﬁc DC distribution and dynamics (41).
Withthekineticsofantigendistributionanditsdependenceon
theantigenandimmunizationroutehavingbeencharacterized,it
FIG 4 In vivo ﬂuorescence imaging to measure antigen deposition after MN delivery. Kinetics of trafﬁcking of (A) PR8 Qdot-labeled (PR8 Qdot) after MN
vaccinationand(B)MN-deliveredstreptavidin-Alexa750.Imageswerecapturedat10min(d0)anddays1,2,3,7,14,and21afterMNdelivery.Representative
images from three or four mice each in the PR8 Qdot and streptavidin-A750 groups are shown. *, indicates that the exposure time has been doubled.
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populations involved in antigen presentation after inactivated-
virus MN immunization. Moreover, the recent use of antibodies
to target antigens to speciﬁc DC subsets has demonstrated the
potential to enhance the magnitude of the adaptive immune re-
sponse (42). The changes in speciﬁc innate cells and the skin cy-
tokine proﬁle generated after vaccination are important parame-
ters in characterizing the mechanisms involved in responses to
skin immunization.
MATERIALS AND METHODS
Microneedles.Solidmetalmicroneedleswerefabricatedbyetchingstain-
less steel sheets (McMaster-Carr, Atlanta, GA) to measure 700 m tall,
withacross-sectionalareaof170mby55matthebaseandtaperingto
asharptip.Themicroneedlesconsistedofﬁveneedlesperarray.Acoating
solution was formulated with 1% (wt/vol) carboxymethylcellulose
(Carbo-Mer, San Diego, CA), 0.5% (wt/vol) Lutrol F-68NF (BASF, Flo-
rham Park, NJ), and 15% (wt/vol) d-()-trehalose dihydrate (Sigma, St.
Louis, MO). This coating solution contained inactivated A/Puerto Rico/
8/34 (PR8) virus, ﬂuorescently labeled PR8, ovalbumin-Alexa Fluor 488,
orAlexaFluor750(Invitrogen,Eugene,OR).Microneedleswerecoatedas
described previously (13).
Inﬂuenza virus. Inﬂuenza virus was grown in the allantoic cavities of
chicken eggs, puriﬁed, and inactivated as described (43). To assess virus
titers, hemagglutination (HA) activity was determined using chicken red
blood cells (LAMPIRE Biological Laboratories, Pipersville, PA) and by a
proteinconcentrationassay(Bio-RadLaboratories,Hercules,CA),aspre-
viously described (44). Inactivated PR8 virus was labeled using the EZ-
link sulfo NHS-L-C biotin reagent (Thermoscientiﬁc, Rockford, IL) fol-
lowing the manufacturer’s instructions, followed by labeling with
streptavidin Qdot 655 or Qdot 705 (Invitrogen, Eugene, OR). To remove
excess biotin and other reagents between steps, the samples were dialyzed
against phosphate-buffered saline (PBS) overnight.
Immunizations. Emory University’s Institutional Animal Care and
Use Committee (IACUC) approved all animal procedures. Six- to eight-
week-old female BALB/c mice (Charles River Laboratory, Wilmington,
MA) and NCr nude mice (Taconic, Hudson, NY) were vaccinated with
10 g of model antigen which had been used to coat MN arrays (inacti-
vated labeled PR8 virus, ovalbumin-Alexa Fluor 488, or streptavidin-
Alexa Fluor 750) or via the intramuscular (IM) route. MN immunization
was performed in anesthetized mice, 48 h after dorsal caudal skin treat-
ment with hair removal cream (Nair; Church & Dwight Co. Inc., Prince-
ton, NJ). MN arrays were left inserted in the skin for 5 min to ensure that
the coating antigen was delivered. Naive mice and mice receiving mock
vaccination with MN lacking antigen were used as negative control
groups.
Detection of skin cytokines. Skin surrounding the insertion site (ap-
proximately 0.5 cm2) was dissected 6 or 12 h postimmunization and pro-
cessed for tissue cytokine analysis as previously described (45). Cytokine
analysis was performed using a mouse 31-plex Luminex cytokine assay at
the BIIR Luminex Core (Dallas, TX).
Migration assays and ﬂow cytometry. For migration assays, coated
MN arrays were used to immunize mice on the dorsal ear surface. Ears
were collected at 10 min, 30 min, 2 h, 24 h, and 48 h postimmunization
and used to establish skin organ cultures. Murine ear skin explants were
performed as previously described (46). Brieﬂy, the ears were split into
dorsal and ventral halves and placed in Transwell plates (Corning Inc.,
Lowell, MA) in RPMI supplemented with fetal calf serum and penicillin/
streptomycin.Migratorycellswereharvested72hlaterandwashedin1%
bovine serum albumin in PBS. Cells collected from each Transwell plate,
corresponding to one auricular tissue sample, were analyzed indepen-
dently by surface staining with ﬂuorochrome-conjugated anti-mouse
CD11c,MHCclassII,CD40,CD86,CD205,orCD8antibodiespurchased
from eBioscience (San Diego, CA) or BD Bioscience Pharmingen (San
Diego, CA). The data were acquired on a BD Biosciences LSRII ﬂow cy-
tometer and analyzed using FlowJo software (v6.3.3; Tree Star Inc., San
Diego, CA).
In vivo ﬂuorescence imaging. Shaved mice were anesthetized with a
ketamine-xylazine cocktail intraperitoneally and immunized with 25 g
of ovalbumin-Alexa Fluor 488 using coated MN or via IM injection. Im-
ages were obtained using the LT9-PANSEE panoramic imaging system
(Lightools Research, Encinitas, CA) at 10 min, 24 h, 48 h, and 72 h.
Ovalbumin 488 (OVA 488) was visualized using a green ﬁlter for excita-
tion (470/40 nm) and 515 nm emission at an exposure time of 200 ms for
MNand400msforIMgroups.Measurementsofinjectionsiteintegrated
density were made by analyzing digital photographs using the software
program ImageJ (NIH Research Services Branch, Bethesda, MD). Qdot
705-labeled virus (5 g) or streptavidin Alexa Fluor 75-labeled MN-
immunized nude mice were imaged using the CRi Maestro EX in vivo
imaging system (Cambridge Research and Instrumentation, Woburn,
MA). To capture the image for the Qdot 705 ﬂuorochrome, the illumina-
tion ﬁlter was set on orange at 605 nm and the emission ﬁlter was set on
yellow at 635 nm.
The ﬁlter settings in Alexa Fluor 750 experiments were deep red at
661nmfortheilluminationﬁlteranddeepredat700nmfortheemission
ﬁlter.Thespectralresolutionforallimagingwas10nm.Measurementsof
theinjectionsiteintegratedintensityweremadebyanalyzingdigitalpho-
tographs using the software Matlab version 2010a (MathWorks, Natick,
MA).
Statistics. Data are given as means  standard deviations (SD), and
thenumberofanimalsperexperimentalgroupwasthreetoﬁve.Statistical
signiﬁcancewasdeterminedforgroupeddatabyone-wayanalysisofvari-
ance with GraphPad Prism software. P values of 0.05 were considered
signiﬁcant.
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TABLE 2 Integrated ﬂuorescence density in the skin of MN-immunize
mice
Group Density (mean  SD)a %
Alexa 750
d0 22.90  106  0.61  106 100
d1 3.17  106  0.67  106 14
d2 1.89  106  0.47  106 8
d3 0.66  106  0.19  106 3
d5 0.15  106  0.15  106 1
PR8-Qdot
d0 1.80  106  0.46  106 100
d1 0.75  106  0.12  106 42
d2 0.14  106  0.05  106 8
d3 0.13  106  0.06  106 7
d5 0.08  106  0.01  106 4
a The signal intensity was quantiﬁed using ImageJ software at the injection site from
images captured day 0 through day 5 after MN delivery.
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